<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378674</url>
  </required_header>
  <id_info>
    <org_study_id>CUSacredHeart</org_study_id>
    <nct_id>NCT03378674</nct_id>
  </id_info>
  <brief_title>Remifentanil and Stress Hormones Response</brief_title>
  <official_title>Effect of Different Doses of Remifentanil on Stress Response During Laparoscopic Cholecystectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Perioperative adequate analgesia reduces neuroendocrine stress response and postoperative
      complications. Because opioids are the most effective parenteral drugs to control pain and
      stress response, in this prospective randomized double-blinded controlled study we supposed
      that higher dose of remifentanil may reduce stress marker variations compared to lower dose
      in patients undergoing laparoscopic cholecystectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifty Caucasian patients, aged 20-70 years, with American Society of Anesthesiologist
      physical status I-II, undergoing laparoscopic cholecystectomy were enrolled. Exclusion
      criteria were: patient refusal, thyroid disorders, diabetes mellitus, BMI &gt; 30, use of
      corticosteroids, benzodiazepines or antipsychotics drugs. No patient received premedication.
      Before entering the operating room, venous access was established (18 G in the antecubital
      vein) where the first blood sample (Time 0) was collected to measure adrenocorticotropic
      hormone (ACTH), Cortisol, Growth hormone (GH) and prolactin (PRL) levels. Then a second
      venous access was established (18 G on the other arm) to start a fluid infusion (normal
      saline to replace half of the water deficit from preoperative fasting followed by a
      maintenance infusion of 2 ml/kg/h). Heart Rate (HR), Non Invasive Blood Pressure (NIBP),
      Bispectral Index (BIS), End-tidal CO2 (EtCO2) were recorded every 5 minutes. Patients were
      randomly assigned to receive two different dosages of remifentanil: 0,15 mcg/kg/min (group A)
      and 0,30 mcg/kg/min (group B) for the induction and the maintenance of anesthesia, using a
      computer generated randomization table (Table I). Anesthesia was induced with propofol 2
      mg/kg, cisatracurium 0,15 mg/kg and remifentanil infusion of 0,15 mcg/Kg/min (Group A) or 0,3
      mcg/Kg/min (Group B) was started. Anesthesia was maintained with desflurane at a variable
      concentration in order to maintain the BIS between 40 and 60. The second blood sample was
      collected at the trocar insertion (Time 1), and the third sample one hour after the end of
      the surgery (Time 2). Postoperative analgesia was standardized using intravenous
      acetaminophen 1 g and morphine 0,1 mg/kg 30 minutes before the end of the surgery. Rescue
      analgesia in Recovery Room was provided by intravenous tramadol 1 mg/Kg.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACTH levels changes</measure>
    <time_frame>changes between basal, incision,one hour after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cortisol levels changes</measure>
    <time_frame>changes between basal, incision,one hour after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Growth hormone levels changes</measure>
    <time_frame>changes between basal, incision,one hour after surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>prolactin levels changes</measure>
    <time_frame>changes between basal, incision,one hour after surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Stress Response</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>remifentanil infusion of 0,15 mcg/Kg/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>remifentanil infusion of 0,3 mcg/Kg/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Injectable Product</intervention_name>
    <description>remifentanil: 0,15 mcg/kg/min</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  American Society of Anesthesiologist physical status I-II

          -  Undergoing laparoscopic cholecystectomy

        Exclusion Criteria:

          -  patient refusal,

          -  thyroid disorders,

          -  diabetes mellitus,

          -  BMI &gt; 30,

          -  use of corticosteroids, benzodiazepines or antipsychotics drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Flaminio Sessa, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University Rome</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catholic University of Sacred Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Jakeways MS, Mitchell V, Hashim IA, Chadwick SJ, Shenkin A, Green CJ, Carli F. Metabolic and inflammatory responses after open or laparoscopic cholecystectomy. Br J Surg. 1994 Jan;81(1):127-31.</citation>
    <PMID>8313088</PMID>
  </reference>
  <reference>
    <citation>Marana E, Scambia G, Maussier ML, Parpaglioni R, Ferrandina G, Meo F, Sciarra M, Marana R. Neuroendocrine stress response in patients undergoing benign ovarian cyst surgery by laparoscopy, minilaparotomy, and laparotomy. J Am Assoc Gynecol Laparosc. 2003 May;10(2):159-65.</citation>
    <PMID>12732764</PMID>
  </reference>
  <reference>
    <citation>Adas G, Kemik A, Adas M, Koc B, Gurbuz E, Akcakaya A, Karahan S. Metabolic and inflammatory responses after ERCP. Int J Biomed Sci. 2013 Dec;9(4):237-42.</citation>
    <PMID>24711760</PMID>
  </reference>
  <reference>
    <citation>Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000 Jul;85(1):109-17. Review.</citation>
    <PMID>10927999</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2017</study_first_submitted>
  <study_first_submitted_qc>December 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Germano De Cosmo</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

